BeOne Strengthens Its BTK Position at ASH
BeOne Medicines presented six‑year follow‑up data for its BTK inhibitor Brukinsa (zanubrutinib) at the ASH meeting, showing roughly 75% of treatment‑naïve chronic lymphocytic leukemia (CLL) patients remain progression‑free. The company also shared early results from a novel BTK degrader that serves as the entry point for a broader protein‑degradation platform. Phase III trials confirmed Brukinsa’s long‑term safety and efficacy in both first‑line and relapsed settings, reinforcing its position as the market‑leading BTK inhibitor. These findings underpin BeOne’s strategy to expand beyond inhibition toward targeted protein degradation.
House Passes BIO-Backed Legislation to Increase Access to Capital
The U.S. House of Representatives approved the Incentivizing New Ventures and Economic Strength Through Capital Formation (INVEST) Act on Dec. 11, passing it 302‑123 with bipartisan support. The legislation, championed by BIO, aims to remove regulatory hurdles and expand capital access...
Fifteen Gift Ideas for a Biotech Enthusiast This Holiday Season
The article curates fifteen holiday gift ideas tailored for biotechnology enthusiasts, ranging from playful items like the Viral board game to advanced tools such as portable DNA sequencers. It highlights novelty products—including glow‑in‑the‑dark mushrooms, DNA‑shaped cookie cutters, and personalized DNA...
Tackling Pulmonary Fibrosis: Boehringer Ingelheim’s New Drug + AI Approach
Boehringer Ingelheim has launched the first new pulmonary‑fibrosis medicine in more than a decade, an oral PDE4B inhibitor that secured FDA approval and will be rolled out globally. The company also introduced eLung, an AI‑driven imaging tool that spots microscopic...
Lilly’s Triple Agonist Contender for Best-in-Class Weight Loss
Eli Lilly announced Phase III TRIUMPH-4 data for its triple‑agonist retatrutide, showing a 26.6% placebo‑adjusted weight loss after 68 weeks at the 12 mg weekly dose. The study enrolled 445 obese adults with knee osteoarthritis, and the highest dose translated to...
BioCentury’s FDA Survey Reflects an Industry in Distress
BioCentury’s 2025 FDA survey paints a picture of deep distress across biopharma, flagging “inconsistency” as the sector’s most pressing worry. Respondents praised FDA staff effort but argued senior leadership decisions appear driven by political agendas rather than science. The perceived...
Front Row with BioCentury: Inside the Turbulent Ride of Cell and Gene Therapy
Cell and gene therapy continues to attract attention despite a recent wave of setbacks that have slowed commercial momentum. Manufacturing complexities, heightened regulatory scrutiny, and pricing debates are creating a turbulent environment for developers. Nevertheless, breakthrough scientific data and expanding...
Science Spotlight: Chinese Researchers Advance PROTAC Design
Chinese scientists have unveiled a next‑generation PROTAC scaffold that delivers oral bioavailability and heightened target selectivity. The platform successfully degrades previously undruggable proteins, including KRAS(G12C), and demonstrates tumor‑growth inhibition in mouse models. By integrating AI‑guided linker optimization, the researchers mitigated...
Charlotte Emerging as a Global Leader in Health Care Innovation and Med Tech
Charlotte, long known as a U.S. financial hub, has launched The Pearl—a $75 million health‑care innovation district—in midtown in June 2025. The campus brings together IRCAD North America, Wake Forest University School of Medicine, global med‑tech firms, startup labs, and an AI‑driven clinical‑trial...